EXEL vs TLRY · P/E 17, rev $628.7M vs rev $915.5M
Exelixis Inc (EXEL) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Exelixis Inc (EXEL) is a biotechnology company listed on US.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported EXEL revenue for 2026-07-03 was $628.7M. Net income was $212.1M. Revenue was up 2.9% from 2026-04-03 to 2026-07-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the EXEL and TLRY stock pages for the full models.
Not investment advice.